Novo Nordisk submits diabetes pill for U.S. approvalCardiovascular, Chronic Kidney Disease, FDA, FDA/Regulatory, Glucagon-Like Peptide-1 (GLP-1) Analogs, Injections, New Drug Application (NDA), Non-alcoholic steatohepatitis (NASH), Obesity, Oral insulin, Pills, Type 2 DiabetesNovo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States. Read more March 20, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-03-20 10:52:592019-03-20 13:05:35Novo Nordisk submits diabetes pill for U.S. approval
